专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2018136913A1 INHIBITION OF BONE LOSS AND INHIBITION OF ARTHRITIS BY CTHRC1 审中-公开
公开(公告)号：WO2018136913A1
公开(公告)日：2018-07-26
申请号：PCT/US2018/014780
申请日：2018-01-23
申请人： MAINE MEDICAL CENTER RESEARCH INSTITUTE
发明人： LINDNER, Volkhard , JIN, Yong-Ri
IPC分类号： A61K38/17 , A61P19/10 , A61P19/02
CPC分类号： A61K38/1709 , A61P19/02 , A61P19/10
摘要： The invention features compositions and methods for inhibiting bone loss and arthritis.

2. 发明申请

WO2016196560A1 ENHANCING THE THERAPEUTIC ACTIVITY OF AN IMMUNE CHECKPOINT INHIBITOR 审中-公开
标题翻译：增强免疫检查点抑制剂的治疗活性
公开(公告)号：WO2016196560A1
公开(公告)日：2016-12-08
申请号：PCT/US2016/035169
申请日：2016-06-01
申请人： MAINE MEDICAL CENTER RESEARCH INSTITUTE
发明人： BROOKS, Peter C. , CARON, Jennifer M. , CONTOIS, Liangru
IPC分类号： A61K39/395 , A61K35/35 , A61K38/39 , C07K14/435 , C07K14/78
CPC分类号： A61K39/3955 , A61K38/39 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/507 , C07K14/78 , C07K16/18 , C07K16/2827 , C07K2317/34 , C07K2317/70 , C07K2317/73 , C07K2317/76
摘要： The present invention provides antagonists and methods of use thereof in the treatment of cancer and abnormal immune suppression diseases.
摘要翻译：本发明提供拮抗剂及其在治疗癌症和异常免疫抑制疾病中的应用方法。

3. 发明申请

WO2015130935A1 CULTURE CONDITIONS FOR EXPANSION OF NEPHRON PROGENITOR CELLS 审中-公开
标题翻译：用于扩增NEPHRON PROGENITOR细胞的文化条件
公开(公告)号：WO2015130935A1
公开(公告)日：2015-09-03
申请号：PCT/US2015/017757
申请日：2015-02-26
申请人： MAINE MEDICAL CENTER RESEARCH INSTITUTE
发明人： OXBURGH, Leif , BROWN, Aaron
IPC分类号： C12N5/02 , C12N5/07 , C12N5/071
CPC分类号： C12N5/0018 , C12N5/0686 , C12N5/0687 , C12N2501/105 , C12N2501/119 , C12N2501/155 , C12N2501/415 , C12N2501/727 , C12N2501/91 , C12N2501/999
摘要： The present invention relates to compositions and methods associated with cocktails of growth factors and small molecules that target specific cell signaling pathways, the cocktails having been formulated to allow/promote the expansion of progenitor cells (e.g., nephron progenitor cells) within a defined culture system.
摘要翻译：本发明涉及与生长因子的鸡尾酒和靶向特定细胞信号传导途径的小分子相关的组合物和方法，所述鸡尾酒已配制成允许/促进在限定的培养系统内的祖细胞（例如，肾单位祖细胞）的扩增。

4. 发明申请

WO2004078944A2 COMPOSITIONS, METHODS AND KITS RELATING TO THROMBIN, NOTCH SIGNALING AND STAMATOGENESIS AND GROWTH OF STEM CELLS 审中-公开
标题翻译：组合物，与硫蛋白相关的方法和工具，Notch信号和STAMATOGENESISIS和STEM细胞的生长
公开(公告)号：WO2004078944A2
公开(公告)日：2004-09-16
申请号：PCT/US2004/006762
申请日：2004-03-05
申请人： MAINE MEDICAL CENTER RESEARCH INSTITUTE , MACIAG, Thomas , KOLEV, Vihren , VERDI, Joseph, M.
发明人： MACIAG, Thomas , KOLEV, Vihren , VERDI, Joseph, M.
IPC分类号： C12N
CPC分类号： C12N5/0623 , C12N2501/42 , C12N2501/998
摘要： The present invention relates to methods based on the interactions of thrombin as a biological regulator. More specifically, the invention relates to the interactions of thrombin with regard to Notch signaling, Jaggedl, PAR1, and cellular effects mediated thereby. The invention relates to the discovery that thrombin cleaves Jagged l to produce non-membrane soluble Jagged l (sJl). The soluble Jagged l protein can affect Notch signaling and, among other things, mediate the release of FGF-1 and/or IL-lα from a cell. The invention further relates to the role(s) of thrombin and signaling via Notch proteins and the effect on thrombosis, angiogenesis, and/or differentiation, among other processes. Moreover, the invention relates to discovery that thrombin, sJl, and TRAP mediate, inter alia , rapid non-classical release of FGF-1, and proteins associated therewith ( e.g. , p40 Synl and S100A13, among others), and the effect growth and proliferation of a stem cell without loss of differentiation potential. Thus, the present invention relates to methods of clonally expanding a pluripotent stem cell while preserving the differentiation potential of the cell, a process termed "stamatogenesis."
摘要翻译：本发明涉及基于凝血酶作为生物调节剂的相互作用的方法。更具体地，本发明涉及凝血酶与Notch信号传导，Jagged1，PAR1以及由此介导的细胞效应的相互作用。本发明涉及凝血酶切割锯齿状I以产生非膜可溶性Jagged l（sJ1）的发现。可溶性Jagged I蛋白可以影响Notch信号传导，并且其中包括从细胞介导FGF-1和/或IL-1α的释放。本发明还涉及凝血酶的作用和通过Notch蛋白的信号通路以及其他过程中对血栓形成，血管生成和/或分化的作用。此外，本发明涉及发现凝血酶，sJ1和TRAP尤其介导FGF-1的快速非经典释放和与其相关的蛋白质（例如，p40 Synl和S100A13等），以及效应生长和干细胞的增殖而不损失分化潜能。因此，本发明涉及克隆扩增多能干细胞同时保持细胞的分化潜能的方法，称为“致死生成”的过程。

5. 发明申请

WO2003052378A2 COMPOSITIONS, METHODS AND KITS RELATING TO THROMBIN DEGRADATION RESISTANT FIBROBLAST GROWTH FACTOR-1 审中-公开
标题翻译：组合物，与硫蛋白降解抗性成纤维细胞生长因子-1相关的方法和试剂盒
公开(公告)号：WO2003052378A2
公开(公告)日：2003-06-26
申请号：PCT/US2002/039686
申请日：2002-12-11
申请人： REPAIR, INC. , MAINE MEDICAL CENTER RESEARCH INSTITUTE , MACIAG, Thomas , ETTENSON, David, S. , BURGESS, Wilson, H. , DROHAN, William, N.
发明人： MACIAG, Thomas , ETTENSON, David, S. , BURGESS, Wilson, H. , DROHAN, William, N.
IPC分类号： G01N
CPC分类号： C07K14/501
摘要： The invention relates to novel degradation resistant FGF-1, and methods for producing and using the same. More specifically, the invention relates to identification of a thrombin degradation resistant FGF-1, and a nucleic acid encoding the same. The thrombin degradation resistant FGF-1 can elicit responses that are otherwise typically impeded by degradation of FGF-1 by thrombin. Thrombin degradation resistant FGF-1 is an important molecule for effecting an FGF-1 response that would be otherwise inhibited by thrombin. Thus the present invention provides a powerful therapeutic for diseases or disorders wherein an FGF-1 response can mediate a reduction in the frequency or intensity of a symptom of the disease or disorder but for degradation of FGF-1 before it can effect the response.
摘要翻译：本发明涉及新型降解抗性FGF-1及其生产和使用方法。更具体地，本发明涉及凝血酶降解抗性FGF-1的鉴定和编码该凝血酶降解的核酸。凝血酶降解抗性FGF-1可引发其他通常受凝血酶降解FGF-1阻碍的反应。凝血酶降解抗性FGF-1是影响凝血酶另外抑制的FGF-1应答的重要分子。因此，本发明为疾病或病症提供了强大的治疗剂，其中FGF-1应答可以介导疾病或病症症状的频率或强度的降低，但是在其能够影响反应之前，可以降解FGF-1。

6. 发明申请

WO2003018595A3 COPPER-DEPENDENT NON-TRADITIONAL PRO-INFLAMMATORY CYTOKINE EXPORT AND METHODS, COMPOSITIONS AND KITS RELATING THERETO 审中-公开
公开(公告)号：WO2003018595A3
公开(公告)日：2003-03-06
申请号：PCT/US2002/027247
申请日：2002-08-26
申请人： MAINE MEDICAL CENTER RESEARCH INSTITUTE , MACIAG, Thomas , MANDINOVA, Anna , MANDINOV, Lazar , PRUDOVSKY, Igor , BELLUM, Stephen , SOLDI, Raffaella , BAGALA, Cinzia
发明人： MACIAG, Thomas , MANDINOVA, Anna , MANDINOV, Lazar , PRUDOVSKY, Igor , BELLUM, Stephen , SOLDI, Raffaella , BAGALA, Cinzia
IPC分类号： A61K38/20
摘要： The present invention relates to the discovery that non-traditional export of certain pro-inflammatory cytokines lacking a signal sequence from a cell can be inhibited by copper chelation and/or administration to the cell of a truncated form of S100A13 lacking the basic residue portion. Further, copper chelation inhibits, inter alia , neointima formation, macrophage infiltration and associated inflammation, cell proliferation, secretion, macrophage infiltration and associated inflammation, cell proliferation, secretion of extracellular matrix, intimal thickening, adventitial angiogenesis, restenosis, and the like, associated with vascular vessel injury. Thus, the present invention provides novel methods for preventing and treating, and for identifying novel compounds also useful as therapeutics for, such conditions.

7. 发明申请

WO2019140151A1 METHODS, COMPOSITIONS, AND KITS FOR PRODUCING BEIGE ADIPOCYTES AND TREATING METABOLIC DISORDERS 审中-公开
公开(公告)号：WO2019140151A1
公开(公告)日：2019-07-18
申请号：PCT/US2019/013140
申请日：2019-01-11
申请人： MAINE MEDICAL CENTER RESEARCH INSTITUTE
发明人： BROWN, Aaron C.
IPC分类号： A61P3/04 , A61P3/06 , A61P3/10
摘要： Provided herein are, inter alia, methods, compositions, and kits for producing adipocyte populations such as beige adipocyte populations. Also included are methods and compositions for increasing the level of adipocyte populations (e.g., beige adipocyte populations) in a subject, as well as methods and compositions for treating subjects who are overweight, obese, or who have diabetes.

8. 发明申请

WO2017143115A3 ENHANCING THE THERAPEUTIC ACTIVITY OF AN IMMUNE CHECKPOINT INHIBITOR 审中-公开
标题翻译：增强免疫检查点抑制剂的治疗活性
公开(公告)号：WO2017143115A3
公开(公告)日：2017-08-24
申请号：PCT/US2017/018255
申请日：2017-02-17
申请人： MAINE MEDICAL CENTER RESEARCH INSTITUTE
发明人： BROOKS, Peter, C. , CARON, Jennifer, M.
IPC分类号： C07K16/00 , C07K16/28
摘要： The present invention provides antagonists and methods of use thereof in the treatment of cancer and abnormal immune suppression diseases.
摘要翻译：本发明提供拮抗剂及其在治疗癌症和异常免疫抑制疾病中的使用方法。

9. 发明申请

WO2017143115A2 ENHANCING THE THERAPEUTIC ACTIVITY OF AN IMMUNE CHECKPOINT INHIBITOR 审中-公开
公开(公告)号：WO2017143115A2
公开(公告)日：2017-08-24
申请号：PCT/US2017/018255
申请日：2017-02-17
申请人： MAINE MEDICAL CENTER RESEARCH INSTITUTE
发明人： BROOKS, Peter, C. , CARON, Jennifer, M.
IPC分类号： C07K16/28
CPC分类号： C07K16/2848 , A61K38/39 , A61K2039/505 , C07K16/18 , C07K16/2818 , C07K16/2827 , C07K16/2842 , C07K16/3015 , C07K16/3023 , C07K16/3038 , C07K16/3046 , C07K16/3053 , C07K16/3061 , C07K16/3069 , C07K2317/34 , C07K2317/76
摘要： The present invention provides antagonists and methods of use thereof in the treatment of cancer and abnormal immune suppression diseases.

10. 发明申请

WO2006098758A2 COMPOSITIONS, METHODS AND KITS RELATING TO CTHRC1, A NOVEL MODULATOR OF COLLAGEN MATRIX 审中-公开
标题翻译：关于CTHRC1的组合物，方法和工具，胶原蛋白的新型调节剂
公开(公告)号：WO2006098758A2
公开(公告)日：2006-09-21
申请号：PCT/US2005/030005
申请日：2005-08-24
申请人： MAINE MEDICAL CENTER RESEARCH INSTITUTE , LINDNER, Volkhard
发明人： LINDNER, Volkhard
IPC分类号： A01K67/00 , C07H21/04 , A61K39/395 , A61K39/00 , C07K14/785
CPC分类号： C07K14/78 , A01K67/0275 , A01K2217/05 , A01K2227/105 , A01K2267/035 , A61K38/00 , A61K2039/505 , C07K14/4702 , C07K14/51 , C07K16/18 , C07K2319/00 , C07K2319/41 , C07K2319/60 , C12N15/8509
摘要： The invention relates to a novel CTHRC1 nucleic acid and protein encoded thereby. Expression of CTHRC1 is induced by injury in, among others, arteries and skin, and CTHRC1 is expressed in bone, cartilage, kidney, lung and brain. CTHRC1 expression is associated with collagen matrix production, arterial remodeling, arterial restenosis, constrictive remodeling, vessel injury, ectopic ossification, fibrosis, and the like. CTHRC1 also plays a role in cell-cell and cell-matrix adhesion, cell-migration, and bone, cartilage, skin and brain development. CTHRC1 also regulates the level of BMPs, including BMP1 and BMP4, and the invention encompasses methods relating to affecting the level of BMPs by affecting the level of CTHRC1. In addition, the invention relates to modulation of the level of CTHRC1 to affect processes associated with fibrosis mediated by formation of collagen matrix. The invention further relates to methods of treating, preventing, and/or detecting these diseases, disorders or conditions, where the methods comprise modulating or detecting CTHRC1 expression and/or production of CTHRC1 polypeptide. The invention also relates to affecting CTHRC1 expression using cytokines.
摘要翻译：本发明涉及由此编码的新型CTHRC1核酸和蛋白质。 CTHRC1的表达是由动脉和皮肤等损伤引起的，CTHRC1在骨，软骨，肾，肺和脑中表达。 CTHRC1表达与胶原基质产生，动脉重塑，动脉再狭窄，缩窄重塑，血管损伤，异位骨化，纤维化等有关。 CTHRC1也在细胞和细胞 - 基质粘附，细胞迁移和骨，软骨，皮肤和脑发育中发挥作用。 CTHRC1还规定BMPs，包括BMP1和BMP4的水平，本发明包括通过影响CTHRC1水平影响BMP水平的方法。此外，本发明涉及调节CTHRC1的水平以影响与形成胶原基质介导的纤维化相关的过程。本发明还涉及治疗，预防和/或检测这些疾病，病症或病症的方法，其中所述方法包括调节或检测CTHRC1表达和/或产生CTHRC1多肽。本发明还涉及使用细胞因子影响CTHRC1表达。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式